Welcome to our dedicated page for Grail news (Ticker: GRAL), a resource for investors and traders seeking the latest updates and insights on Grail stock.
GRAIL Inc. (GRAL) is a leader in developing blood-based multi-cancer early detection solutions, most notably through its Galleri® test. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives shaping the future of cancer diagnostics.
Access timely announcements about peer-reviewed study results, partnership developments with leading research institutions, and progress in commercializing early detection technologies. Our curated news collection helps stakeholders track GRAIL’s innovations in methylation-based screening and machine learning applications.
Key updates include coverage of clinical validation studies, FDA regulatory communications, and collaborations with healthcare networks. All content is sourced from official releases to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to GRAIL’s latest developments in precision oncology. Check back regularly for insights into how the company is advancing its mission to detect cancer at its most treatable stages.
GRAIL (Nasdaq: GRAL) entered a securities purchase agreement for a private placement expected to raise approximately $325.0 million in gross proceeds by selling 4,639,543 shares of common stock (or pre-funded warrants) at $70.05 per share. The financing included new and existing institutional investors and is expected to close on October 21, 2025, subject to customary conditions.
GRAIL said it will use net proceeds for commercial activities, reimbursement efforts, working capital, and general corporate purposes, and expects current cash, equivalents and investments plus these proceeds to fund operations into 2030, excluding a separate potential $110 million Samsung investment subject to closing conditions.
GRAIL (Nasdaq: GRAL) and University of Oxford will present extended SYMPLIFY results at EDCC on Oct 21, 2025. The 24-month registry follow-up of >6,000 symptomatic participants found that 35.4% (28 of 79) initially classified as false positives were later diagnosed with cancer, raising Galleri's positive predictive value in this symptomatic cohort to 84.2% (from 75.5% in the primary analysis).
Galleri accurately predicted the Cancer Signal Origin (CSO) in 27 of 28 later-diagnosed cases, and in many instances the detected CSO differed from the original referral pathway, suggesting potential to guide more efficient diagnostic workups.
GRAIL (Nasdaq: GRAL) announced positive PATHFINDER 2 results showing the Galleri multi-cancer early detection test increased cancer detection >7-fold when added to USPSTF A and B recommended screenings.
Key metrics from 23,161 performance-analyzable participants (12-month follow-up): cancer signal in 216 (0.93%), cancer diagnosed in 133 (0.57%), PPV 61.6%, specificity 99.6% (0.4% false positive), episode sensitivity 73.7% for 12 cancers causing two-thirds of U.S. cancer deaths and 40.4% for all cancers. More than half (53.5%) of Galleri-detected new cancers were stage I–II. GRAIL plans a PMA submission in H1 2026.
GRAIL (Nasdaq: GRAL) reported PATHFINDER 2 results showing the Galleri® multi-cancer early detection blood test substantially increased cancer detection when added to USPSTF A and B screenings.
In a 35,878-enrolled study (25,578 with ≥12 months follow-up; 23,161 analyzable for performance), adding Galleri produced a >7-fold increase in cancers found within a year versus recommended screenings alone. Galleri detected 216 cancer signals (0.93%) with 133 confirmed cancers (0.57%) and a PPV of 61.6%. Episode sensitivity was 73.7% for 12 high‑mortality cancers and 40.4% for all cancers; specificity was 99.6%. More than half (53.5%) of Galleri‑detected new cancers were stage I–II; Cancer Signal Origin accuracy was 92%.
GRAIL (Nasdaq: GRAL) signed a binding letter of intent with Samsung C&T and Samsung Electronics for a strategic collaboration to commercialize the Galleri® multi-cancer early detection test in Asia.
SCT and SEC plan a combined $110 million equity investment at $70.05 per share, subject to definitive agreements, customary closing conditions and regulatory approvals, with closing expected in early 2026. SCT will be GRAIL's sole distributor in South Korea (possible extension to Japan and Singapore) and will drive adoption while initial testing will occur at GRAIL's U.S. clinical laboratory. SEC and GRAIL will explore data, AI and longitudinal research collaborations. Definitive agreements are targeted for early 2026 and commercial operations to begin after execution.
GRAIL (NASDAQ: GRAL) announced it will present new data for its Galleri® multi-cancer early detection (MCED) test at two major conferences. The company will showcase results from the PATHFINDER 2 study, the largest MCED interventional study in the U.S., at the ESMO Congress 2025 in Berlin. The study's top-line results demonstrated that adding Galleri to standard screening led to significantly improved cancer detection and higher positive predictive value compared to the first PATHFINDER study.
Additionally, GRAIL will present data from the SYMPLIFY study focusing on symptomatic participants and the REFLECTION study examining real-world experience in veterans at the Early Detection of Cancer Conference (EDCC) 2025 in Portland. The results will be part of GRAIL's FDA Premarket Approval Application for Galleri.
GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the upcoming Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum. The company's management will deliver their presentation on Wednesday, September 24, 2025, at 8:00 a.m. ET.
Investors and interested parties can access both the live webcast and replay through GRAIL's investor relations website at investors.grail.com. The presentation recording will remain available for a minimum of 30 days following the event.
GRAIL (NASDAQ: GRAL), a healthcare company focused on early cancer detection, has announced the granting of equity awards to 27 newly hired non-executive employees. The awards consist of restricted stock units (RSUs) totaling 47,150 shares of GRAIL's common stock.
The RSUs were granted under GRAIL's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule spans approximately four years, with 25% vesting on August 31, 2026, and the remaining portions vesting annually thereafter, contingent on continued employment.
GRAIL (NASDAQ:GRAL), a healthcare company focused on early cancer detection, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will deliver their presentation on Tuesday, September 9 at 1:50 p.m. ET.
Investors can access both the live presentation and replay through GRAIL's investor relations website at investors.grail.com. The webcast recording will remain available for a minimum of 30 days following the event.
GRAIL (NASDAQ: GRAL) reported its Q2 2025 financial results, showing significant growth in its cancer detection business. Total revenue increased 11% year-over-year to $35.5 million, with U.S. Galleri revenue growing 21% to $34.2 million. The company sold over 45,000 Galleri tests in Q2, representing 29% growth year-over-year.
The company reported a net loss of $114.0 million, which includes a $28.0 million impairment of Illumina acquisition-related intangibles. GRAIL's PATHFINDER 2 study showed promising results, with improved cancer detection rates and higher positive predictive value compared to the first PATHFINDER study. The company maintained strong liquidity with $606.1 million in cash and equivalents as of June 30, 2025.
FAQ
What is the current stock price of Grail (GRAL)?
What is the market cap of Grail (GRAL)?
